Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Synthetic derivative of curry spice can be effective neuroprotective for stroke and TBI

Synthetic derivative of curry spice can be effective neuroprotective for stroke and TBI

Over expression of transcription factor improves neurological function in HD transgenic mice models

Over expression of transcription factor improves neurological function in HD transgenic mice models

Small molecules show promise in protecting brain cells against nerve-degenerative diseases

Small molecules show promise in protecting brain cells against nerve-degenerative diseases

New analysis shows that common diseases are not lined to genetic factors

New analysis shows that common diseases are not lined to genetic factors

EPO upholds Alnylam's Tuschl II 1407044 patent

EPO upholds Alnylam's Tuschl II 1407044 patent

AMT, Amgen amend GDNF gene license agreement

AMT, Amgen amend GDNF gene license agreement

New cerebrospinal fluid biomarkers to monitor Parkinson's disease

New cerebrospinal fluid biomarkers to monitor Parkinson's disease

Alnylam presents data on RNAi technologies at MIT Center Summit

Alnylam presents data on RNAi technologies at MIT Center Summit

Alnylam comments on Roche's corporate restructuring for RNAi therapeutics

Alnylam comments on Roche's corporate restructuring for RNAi therapeutics

Neuralstem files NSI-189 IND with FDA for Phase I safety trials for major depression

Neuralstem files NSI-189 IND with FDA for Phase I safety trials for major depression

Handwriting problems in autistic children likely to continue into teenage years: Study

Handwriting problems in autistic children likely to continue into teenage years: Study

Fisetin slows onset of motor problems, delays death in three models of Huntington's disease: Study

Fisetin slows onset of motor problems, delays death in three models of Huntington's disease: Study

Neurologix third quarter net loss decreases to $2.3 million

Neurologix third quarter net loss decreases to $2.3 million

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Study suggests mid-life cholesterol level may not linked to later development of Alzheimer's disease

Study suggests mid-life cholesterol level may not linked to later development of Alzheimer's disease

Raptor initiates dosing in DR Cysteamine Phase 2 clinical trial for Huntington's Disease

Raptor initiates dosing in DR Cysteamine Phase 2 clinical trial for Huntington's Disease

New findings could help scientists devise optimal therapies for Friedreich's ataxia

New findings could help scientists devise optimal therapies for Friedreich's ataxia

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting

Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting

Neurologix holds license for gene therapy to treat severe depression

Neurologix holds license for gene therapy to treat severe depression

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.